Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes
Our study confirms that telitacicept has a definite proteinuria-lowering effect in IgAN. Extending the treatment duration from 6 months to 9-12 months further enhances its ability to reduce proteinuria.
Authors
- Jing Xu (ORCID: https://orcid.org/0000-0001-6785-9846)
- Jingyuan Xie (ORCID: https://orcid.org/0000-0002-5508-0664)
- Yuanmeng Jin
- Zijin Chen (ORCID: https://orcid.org/0009-0000-4075-1499)
- Qianfeng Weng
- Zhaohui Wang (ORCID: https://orcid.org/0000-0002-4610-4687)
- Jun Ma (ORCID: https://orcid.org/0000-0001-5236-2239)
- Li Xiao (ORCID: https://orcid.org/0000-0002-3053-4930)
- Jian Liu (ORCID: https://orcid.org/0000-0001-5148-5069)
- Pingyan Shen
- Hao Shi (ORCID: https://orcid.org/0000-0002-2773-9206)
- Yan Ouyang (ORCID: https://orcid.org/0000-0002-3181-8708)
- Hong Ren (ORCID: https://orcid.org/0000-0003-3156-6640)
Institutions
- Shanghai Jiao Tong University (CN)
- Ruijin Hospital (CN)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1093/ckj/sfaf154
- Citations
- 11
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 15.74
Funders
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- Shanghai Jiao Tong University
- Shanghai Hospital Development Center
- National Key Research and Development Program of China